CNTB
Connect Biopharma Holdings Limited
There isn't enough reported data to score CNTB yet.
CNTB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
CNTB's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
CNTB PE Valuation
CNTB has no meaningful PE right now: it lost money over the past year.
CNTB Forward outlook
There aren't enough analyst estimates for CNTB to show an outlook.
CNTB Earnings Per Share
CNTB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.8M | +5667% |
| Q2 2025 | $48K | -100% |
CNTB's revenue is recovering but still below its 2024 peak: $3M last quarter, up 5667% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -636% | +27331 points |
| Q1 2026 | -11602% | N/A |
| Q3 2025 | -110481% | -110538 points |
| Q2 2025 | -27967% | N/A |
| Q4 2024 | -1378% | N/A |
| Q2 2024 | 57% | N/A |
CNTB's operating margin was −636% last quarter, up 742 points from the same quarter a year ago.
CNTB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$15.9M | -$3M |
| Q1 2026 | -$16M | -$6M |
| Q4 2025 | -$11.3M | +$4.6M |
| Q2 2025 | -$12.9M | -$4.5M |
| Q4 2024 | -$15.9M | +$961.8K |
| Q2 2024 | -$8.4M | +$23M |
| Q4 2023 | -$16.9M | +$30.1M |
| Q2 2023 | -$31.4M | +$23.2M |
CNTB has burned cash in almost every quarter: −$61M over the past year, against −$47M the year before.
CNTB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +11% | +6.3M shares |
| 1 year | +13% | +7.4M shares |
| 3 years | +34% | +15.9M shares |
CNTB has 63M diluted shares, up 13% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q2 2024 | — |
| Q4 2023 | — |
| Q2 2023 | — |
| Q4 2022 | — |
| Q2 2022 | — |
| Q4 2021 | $5,463 |
| Q2 2021 | $195 |
CNTB Net Leverage
CNTB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CNTB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.0 | Oversold |
| Stochastic | 1.5 | Oversold |
CNTB's weekly RSI is 29 (oversold) and its Stochastic is 1 (oversold).
CNTB PE vs Healthcare Sector
CNTB has no meaningful PE right now: it lost money over the past year.
CNTB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.84 | 20% below |
| 20 week MA | $1.64 | 59% below |
| 50 week MA | $2.15 | 69% below |
| 100 week MA | $1.73 | 61% below |
| 200 week MA | $1.47 | 54% below |
CNTB is in a downtrend: it's below all five of its weekly moving averages, and 54% below its 200-week average.
CNTB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $18.5 | $4.60 | -75% |
| 2022 | $4.60 | $0.76 | -83% |
| 2023 | $0.76 | $1.18 | +55% |
| 2024 | $1.18 | $1.14 | -3.4% |
| 2025 | $1.14 | $2.69 | +136% |
| 2026 YTD | $2.69 | $0.67 | -75% |
CNTB's yearly returns have swung widely, from +136% in 2025 to −83% in 2022. It's down 75% so far in 2026.